I could see a BP operating something like NWBO as a wholly owned subsidiary, but I really don't believe they want to mix mass produced products with personalized products. They might be willing to somewhat personalize a product, so say 10 variations exist of something that treats a million patients, so on average they make 100,000 doses of each, but they really don't want to have a million patients who's products are different from each other and they must make, store, and deliver them as needed. Best to keep technology, like that of NWBO's, in a completely different organization than one where products are made by the millions.
Don't get me wrong, the profits from personalized products can be tremendous, I just don't believe that you want to make them in the same facility that's producing other products by the millions. If the BP's cannot equal the efficacy of DCVax-L with mass produced products they certainly may want to own it, but they'll keep it separate from all their other operations.
Gary
News 
Market Data 
Discover 
